Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies

被引:18
|
作者
Mison, L
Seed, CR
Margaritis, AR
Hyland, C
机构
[1] Australian Red Cross Blood Serv, Brisbane, Qld, Australia
[2] Australian Red Cross Blood Serv, Perth, WA, Australia
关键词
anti-HCV antibody; blood screening; NAT; seroconversion;
D O I
10.1046/j.1423-0410.2003.00246.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives The aim of this study was to compare the performance of two high-throughput strategies for hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) RNA nucleic acid technology (NAT) screening in a volunteer blood-donor population. Materials and Methods The semiautomated Chiron Procleix HIV-1/HCV transcription mediated amplification (TMA) assay was used to screen 1 439 765 donations in two different testing configurations. Three sites (termed PDT sites) performed a mixture of individual donation (ID) and minipool (MP) testing, where 1 113 288 donations were screened as pools of 24 and an additional 32 003 donations were screened in ID format. A further two sites (termed SDT sites) screened 294 474 donations exclusively in ID format. Results A significantly higher proportion of initial NAT reactives that failed to react on follow-up testing [termed non-repeatably reactive (NRR)] was observed for ID testing at SDT sites than at PDT sites (0.082 vs. 0.047%: P < 0.01). Within the PDT sites, however, there was no significant difference between the NRR rate for MP or ID samples (0.037 vs. 0.047%; not significant). There was a significant difference in failed run rates between PDT and SDT sites (P < 0.01), with PDT sites having a higher run failure rate owing to non-amplification of the internal control. The PDT sites also had a significantly higher overall invalid sample rate. However, the invalid sample rate, specifically caused by known equipment failure, was significantly higher in the SDT sites, possibly attributable to greater usage (P < 0.0001). Four HCV NAT-positive/antibody-negative samples were identified in the course of the study. Conclusions The comparison of the performance of PDT with SDT sites identified only minor differences that did not adversely impact on the timely release of blood products. Although both ID and MP strategies showed excellent specificity, irrespective of site configuration, the significantly increased NRR rate, observed exclusively for ID testing performed at SDT sites, indicates a potential for contamination that may limit the number of samples that can optimally be processed using ID testing. The performance data for ID testing in particular should serve as a useful benchmark for evaluating candidate NAT systems that are fully automated.
引用
收藏
页码:11 / 19
页数:9
相关论文
共 50 条
  • [41] Routine nucleic acid testing of blood donations fails to detect all human immunodeficiency virus-positive blood donors
    Fearon, Margaret
    Scalia, Vito
    Lane, Debra
    Bigham, Mark
    Hawes, Gordon
    O'Brien, Sheila
    Kadkhoda, Kamran
    TRANSFUSION, 2016, 56 (04) : 994 - 995
  • [42] New strategies for blood donor screening for hepatitis B virus - Nucleic acid testing versus immunoassay methods
    Kuhns, MC
    Busch, MP
    MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (02) : 77 - 91
  • [43] False-positive nucleic acid test results for human immunodeficiency virus RNA and hepatitis C virus RNA: an underappreciated problem
    Kakaiya, Ram
    Gordon, Sharon
    Zimmerman, Andrea
    Verlinsky, Rita
    Ahmed, Syeda
    Phillips, Michael
    TRANSFUSION, 2011, 51 (01) : 225 - 226
  • [44] Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States
    Marshall, DA
    Kleinman, SH
    Wong, JB
    AuBuchon, JP
    Grima, DT
    Kulin, NA
    Weinstein, MC
    VOX SANGUINIS, 2004, 86 (01) : 28 - 40
  • [45] Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa
    Vermeulen, Marion
    Lelie, Nico
    Sykes, Wendy
    Crookes, Robert
    Swanevelder, Johanna
    Gaggia, Lilian
    Le Roux, Martin
    Kuun, Eben
    Gulube, Sam
    Reddy, Ravi
    TRANSFUSION, 2009, 49 (06) : 1115 - 1125
  • [46] A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing
    Shan, Hua
    Ren, Fu-rong
    Zhao, Hai-yan
    Zhang, Yuan-zhi
    Wen, Guo-xing
    Yao, Fu-zhu
    Gao, Guo-jing
    Yan, Li-xing
    Jiang, Chao-fu
    Bai, Xu-hua
    Tiemuer, Mei-hei-li
    Tu, Yuan-quan
    Zhu, Fa-ming
    Zheng, You-rong
    Cui, Li
    Liu, Chang-li
    Gong, Xiao-yan
    Lv, Qiu-shuang
    Zheng, Peng
    Ziermann, Rainer
    Ness, Paul
    Wang, Jing-xing
    TRANSFUSION, 2007, 47 (11) : 2011 - 2016
  • [47] High seroprevalence of hepatitis B virus and hepatitis C virus among human immunodeficiency virus carriers in blood donors of Burkina Faso: a need for their screening before HARRT therapy
    Kirakoya-Samadoulougou, F.
    Sanou, M.
    Samadoulougou, S.
    Bakiono, F.
    Kienou, K.
    Koumare, A.
    Dahourou, H.
    Kabore, I.
    Ouattara, S.
    Nebie, Y.
    Speybroeck, N.
    Robert, A.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (07) : E52 - E53
  • [48] A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity
    Parniak, MA
    Min, KL
    Budihas, SR
    Le Grice, SFJ
    Beutler, JA
    ANALYTICAL BIOCHEMISTRY, 2003, 322 (01) : 33 - 39
  • [50] A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus
    Li, Lei
    Chen, Pei-Jer
    Chen, Ming-Hung
    Chak, Kin-Fu
    Lin, Kuo-Sin
    Tsai, Su-Jen Lin
    TRANSFUSION, 2008, 48 (06) : 1198 - 1206